- Home
- KEY vs NTRA Comparison
KEY vs NTRA Comparison
Compare KEY & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- NTRA
- Stock Information
- Founded
- KEY 1825
- NTRA 2003
- Country
- KEY United States
- NTRA United States
- Employees
- KEY N/A
- NTRA N/A
- Industry
- KEY Major Banks
- NTRA Medical Specialities
- Sector
- KEY Finance
- NTRA Health Care
- Exchange
- KEY Nasdaq
- NTRA Nasdaq
- Market Cap
- KEY 20.8B
- NTRA 27.0B
- IPO Year
- KEY N/A
- NTRA 2015
- Fundamental
- Price
- KEY $17.54
- NTRA $205.15
- Analyst Decision
- KEY Buy
- NTRA Strong Buy
- Analyst Count
- KEY 16
- NTRA 16
- Target Price
- KEY $20.41
- NTRA $220.38
- AVG Volume (30 Days)
- KEY 17.9M
- NTRA 1.4M
- Earning Date
- KEY 10-16-2025
- NTRA 11-06-2025
- Dividend Yield
- KEY 4.65%
- NTRA N/A
- EPS Growth
- KEY 34785.88
- NTRA N/A
- EPS
- KEY 0.86
- NTRA N/A
- Revenue
- KEY $5,934,000,000.00
- NTRA $2,116,676,000.00
- Revenue This Year
- KEY $77.14
- NTRA $25.70
- Revenue Next Year
- KEY $6.45
- NTRA $15.42
- P/E Ratio
- KEY $20.37
- NTRA N/A
- Revenue Growth
- KEY 22.30
- NTRA 38.17
- 52 Week Low
- KEY $12.73
- NTRA $125.38
- 52 Week High
- KEY $20.04
- NTRA $212.21
- Technical
- Relative Strength Index (RSI)
- KEY 46.20
- NTRA 65.15
- Support Level
- KEY $17.17
- NTRA $182.20
- Resistance Level
- KEY $18.47
- NTRA $212.21
- Average True Range (ATR)
- KEY 0.38
- NTRA 8.09
- MACD
- KEY 0.05
- NTRA 0.00
- Stochastic Oscillator
- KEY 34.65
- NTRA 75.84
About KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.